Summary
Regeneron Pharmaceuticals, Inc. (REGN) reported a strong third quarter for 2021, demonstrating significant revenue and profit growth driven by robust performance across its key products. Total revenues increased by 55% year-over-year to $3.45 billion, with net product sales growing substantially, notably from EYLEA and Dupixent. The company also saw a significant boost from REGEN-COV, its COVID-19 antibody treatment, which contributed substantially to revenue in the period. Net income rose by an impressive 94% to $1.63 billion, translating to diluted earnings per share of $14.33, a significant increase from the prior year. This strong financial performance reflects the company's expanding commercial reach and the continued success of its late-stage pipeline. Looking ahead, Regeneron's pipeline remains robust, with several key products in advanced clinical development and ongoing regulatory reviews. The company's strategic collaborations, particularly with Sanofi and Bayer, continue to drive significant revenue. Management's focus remains on advancing its broad pipeline of innovative therapies while strategically deploying capital, including ongoing share repurchase programs, to enhance shareholder value. Investors should monitor the company's progress in key therapeutic areas and the impact of ongoing research and development efforts on future growth.
Financial Highlights
46 data points| Revenue | $3.45B |
| R&D Expenses | $665.40M |
| SG&A Expenses | $445.00M |
| Operating Expenses | $1.61B |
| Operating Income | $1.85B |
| Interest Expense | $14.20M |
| Net Income | $1.63B |
| EPS (Basic) | $15.37 |
| EPS (Diluted) | $14.33 |
| Shares Outstanding (Basic) | 106.20M |
| Shares Outstanding (Diluted) | 113.90M |
Key Highlights
- 1Total revenues surged by 55% year-over-year to $3.45 billion for the third quarter of 2021.
- 2Net income increased by 94% to $1.63 billion, with diluted EPS of $14.33.
- 3Significant growth in net product sales was observed for EYLEA (+15%) and Dupixent (+55%), demonstrating continued market strength.
- 4REGEN-COV contributed $676.7 million in net product sales in the U.S. during the quarter, reflecting its importance in COVID-19 treatment.
- 5Collaboration revenue from Sanofi increased by 65% to $581.8 million, driven by strong performance in the Antibody Collaboration.
- 6The company repurchased approximately $190.5 million of its common stock during the quarter under its authorized share repurchase program.
- 7Cash and cash equivalents increased significantly to $3.43 billion as of September 30, 2021.